CA2959943C - Liquid inhalation formulation comprising rpl554 - Google Patents

Liquid inhalation formulation comprising rpl554 Download PDF

Info

Publication number
CA2959943C
CA2959943C CA2959943A CA2959943A CA2959943C CA 2959943 C CA2959943 C CA 2959943C CA 2959943 A CA2959943 A CA 2959943A CA 2959943 A CA2959943 A CA 2959943A CA 2959943 C CA2959943 C CA 2959943C
Authority
CA
Canada
Prior art keywords
rpl554
composition according
liquid
concentration
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2959943A
Other languages
English (en)
French (fr)
Other versions
CA2959943A1 (en
Inventor
Peter Lionel Spargo
Edward James FRENCH
Phillip A. Haywood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verona Pharma Ltd
Original Assignee
Verona Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1416274.7A external-priority patent/GB201416274D0/en
Priority claimed from GBGB1504662.6A external-priority patent/GB201504662D0/en
Application filed by Verona Pharma Ltd filed Critical Verona Pharma Ltd
Publication of CA2959943A1 publication Critical patent/CA2959943A1/en
Application granted granted Critical
Publication of CA2959943C publication Critical patent/CA2959943C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2959943A 2014-09-15 2015-09-15 Liquid inhalation formulation comprising rpl554 Active CA2959943C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1416274.7A GB201416274D0 (en) 2014-09-15 2014-09-15 Formulation
GB1416274.7 2014-09-15
GBGB1504662.6A GB201504662D0 (en) 2015-03-19 2015-03-19 Formulation
GB1504662.6 2015-03-19
PCT/GB2015/052668 WO2016042313A1 (en) 2014-09-15 2015-09-15 Liquid inhalation formulation comprising rpl554

Publications (2)

Publication Number Publication Date
CA2959943A1 CA2959943A1 (en) 2016-03-24
CA2959943C true CA2959943C (en) 2022-08-16

Family

ID=54196992

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2959943A Active CA2959943C (en) 2014-09-15 2015-09-15 Liquid inhalation formulation comprising rpl554

Country Status (27)

Country Link
US (2) US9956171B2 (enExample)
EP (3) EP3494962B1 (enExample)
JP (2) JP6860477B2 (enExample)
KR (1) KR102379309B1 (enExample)
CN (3) CN110051627A (enExample)
AU (3) AU2015316592B2 (enExample)
CA (1) CA2959943C (enExample)
CY (3) CY1120264T1 (enExample)
DK (3) DK3332767T3 (enExample)
ES (3) ES2670025T3 (enExample)
HK (1) HK1249415B (enExample)
HR (3) HRP20180833T1 (enExample)
HU (3) HUE038433T2 (enExample)
IL (1) IL250895B (enExample)
LT (3) LT3193835T (enExample)
MX (1) MX2017003102A (enExample)
MY (1) MY196072A (enExample)
NO (1) NO3193835T3 (enExample)
PH (1) PH12017500479B1 (enExample)
PL (3) PL3193835T3 (enExample)
PT (3) PT3332767T (enExample)
RS (3) RS62252B1 (enExample)
RU (1) RU2699995C2 (enExample)
SG (1) SG11201701854WA (enExample)
SI (3) SI3494962T1 (enExample)
SM (3) SMT201900340T1 (enExample)
WO (1) WO2016042313A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2773142T3 (es) 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
LT3193835T (lt) * 2014-09-15 2018-06-11 Verona Pharma Plc Skysta inhaliuojama vaisto forma, apimanti rpl554
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
HK1251593A1 (zh) 2015-07-24 2019-02-01 豪夫迈‧罗氏有限公司 Bace1抑制剂肽
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
GB201911517D0 (en) 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
PL4092025T3 (pl) * 2020-01-15 2024-10-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Kompozycja farmaceutyczna tricyklicznego związku będącego podwójnym inhibitorem pde3/pde4
GB202002786D0 (en) * 2020-02-27 2020-04-15 Verona Pharma Plc Liquid pharmaceutical composition
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
KR20250040090A (ko) * 2022-08-08 2025-03-21 베로나 파마 피엘씨 액상 약제학적 조성물
CA3263546A1 (en) * 2022-08-08 2024-02-15 Verona Pharma Limited ENSIFENTRINE (RPL-554) FOR THE TREATMENT OF MODERATE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
EP4609864A4 (en) * 2022-10-28 2026-02-18 Jiangsu Hengrui Pharmaceuticals Co Ltd PHARMACEUTICAL COMPOSITION CONTAINING AN ISOQUINOLINONE COMPOUND AND RELATED PREPARATION PROCESS
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
CN121620356A (zh) * 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物
WO2025003643A1 (en) * 2023-06-26 2025-01-02 Verona Pharma Plc Particulate composition comprising ensifetrine
CN122121878A (zh) * 2023-09-06 2026-05-29 维罗纳制药有限公司 用于治疗慢性阻塞性肺病（copd）的恩塞芬汀
US20250249006A1 (en) * 2024-02-05 2025-08-07 Verona Pharma Plc Treatment
WO2025168706A1 (en) * 2024-02-07 2025-08-14 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease
US20250249008A1 (en) * 2024-02-07 2025-08-07 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease
WO2026093383A1 (en) * 2024-10-30 2026-05-07 Verona Pharma Plc Treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
EP1033991B1 (en) 1997-10-09 2002-04-17 Schering Corporation Mometasone furoate suspensions for nebulization
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
DK1165558T3 (da) 1999-03-31 2004-02-09 Vernalis Ltd Pyrimido[6,1-a]isoquinolin-4-on-derivater
US6630169B1 (en) * 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0122031D0 (en) 2001-09-12 2001-10-31 Pfizer Ltd Use of pde4 inhibitors in a dry powder inhaler
RU2440972C2 (ru) * 2004-12-17 2012-01-27 Сипла Лимитед Кристаллический сульфат левосальбутамола, способ его получения и фармацевтическая композиция, содержащая его
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
CA2803459A1 (en) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal compositions thereof
SI2603509T1 (sl) 2010-08-09 2014-10-30 Verona Pharma Plc Kristalinična oblika spojine PIRIMIDIO(6,1-A) IZOKINOLIN-4-ENA
EP2717855A4 (en) * 2011-06-07 2014-11-12 Parion Sciences Inc Methods of Treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
EP2647627A1 (en) * 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
WO2014037727A1 (en) 2012-09-06 2014-03-13 Verona Pharma Plc Carcainium salts
JP6560986B2 (ja) * 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
CN106105056B (zh) * 2014-03-11 2019-07-12 Lg电子株式会社 D2d用户设备在通信系统中发送发现信号的方法和设备
ES2773142T3 (es) 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
LT3193835T (lt) * 2014-09-15 2018-06-11 Verona Pharma Plc Skysta inhaliuojama vaisto forma, apimanti rpl554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Also Published As

Publication number Publication date
MY196072A (en) 2023-03-13
RS62252B1 (sr) 2021-09-30
BR112017005050A2 (pt) 2018-01-23
NO3193835T3 (enExample) 2018-08-04
PL3494962T3 (pl) 2021-12-06
SI3332767T1 (sl) 2019-07-31
ES2730810T3 (es) 2019-11-12
LT3193835T (lt) 2018-06-11
RS57227B1 (sr) 2018-07-31
KR102379309B1 (ko) 2022-03-28
EP3332767B1 (en) 2019-03-20
MX2017003102A (es) 2017-06-14
AU2020203081B2 (en) 2021-08-05
HRP20191122T1 (hr) 2019-09-20
PT3332767T (pt) 2019-06-27
HRP20180833T1 (hr) 2018-06-29
US9956171B2 (en) 2018-05-01
AU2018286571B2 (en) 2020-04-02
CY1124546T1 (el) 2022-07-22
PH12017500479B1 (en) 2021-07-21
EP3332767A1 (en) 2018-06-13
PT3193835T (pt) 2018-03-27
HK1249415B (en) 2019-11-22
CN106794157B (zh) 2021-03-09
CA2959943A1 (en) 2016-03-24
HUE055527T2 (hu) 2021-12-28
EP3193835B1 (en) 2018-03-07
CN110051627A (zh) 2019-07-26
SI3494962T1 (sl) 2021-09-30
WO2016042313A1 (en) 2016-03-24
LT3494962T (lt) 2021-07-26
LT3332767T (lt) 2019-06-25
KR20170054406A (ko) 2017-05-17
RU2699995C2 (ru) 2019-09-12
SMT201800242T1 (it) 2018-07-17
CY1120264T1 (el) 2019-07-10
CY1121698T1 (el) 2020-07-31
NZ767296A (en) 2024-01-26
AU2015316592A1 (en) 2017-03-23
AU2015316592B2 (en) 2020-04-02
CN106794157A (zh) 2017-05-31
JP2017528479A (ja) 2017-09-28
DK3193835T3 (en) 2018-05-07
CN111249260A (zh) 2020-06-09
NZ729796A (en) 2024-01-26
IL250895A0 (en) 2017-04-30
DK3494962T3 (da) 2021-06-21
EP3494962B1 (en) 2021-05-26
PL3193835T3 (pl) 2018-07-31
AU2018286571A1 (en) 2019-01-24
RU2017108432A3 (enExample) 2019-04-01
SMT201900340T1 (it) 2019-07-11
IL250895B (en) 2019-08-29
CN111249260B (zh) 2023-01-10
US20180369139A1 (en) 2018-12-27
AU2020203081A1 (en) 2020-05-28
PL3332767T3 (pl) 2019-10-31
HUE038433T2 (hu) 2018-10-29
NZ767295A (en) 2024-01-26
US20170239178A1 (en) 2017-08-24
JP2019069978A (ja) 2019-05-09
PT3494962T (pt) 2021-06-22
HUE045303T2 (hu) 2019-12-30
EP3494962A1 (en) 2019-06-12
DK3332767T3 (da) 2019-06-24
PH12017500479A1 (en) 2017-07-31
ES2875584T3 (es) 2021-11-10
EP3193835A1 (en) 2017-07-26
JP6860477B2 (ja) 2021-04-14
RU2017108432A (ru) 2018-10-17
HRP20211035T1 (hr) 2021-09-17
US10945950B2 (en) 2021-03-16
SG11201701854WA (en) 2017-04-27
SMT202100479T1 (it) 2021-09-14
ES2670025T3 (es) 2018-05-29
JP6795574B2 (ja) 2020-12-02
RS58897B1 (sr) 2019-08-30
SI3193835T1 (en) 2018-06-29

Similar Documents

Publication Publication Date Title
AU2020203081B2 (en) Liquid inhalation formulation comprising RPL554
HK1249415A1 (en) Liquid inhalation formulation comprising rpl554
ES2970571T3 (es) Composición farmacéutica líquida que comprende ensifentrina y glicopirrolato
US20240041805A1 (en) Pharmaceutical compositions of niclosamide and a protein
HK40007474B (en) Liquid inhalation formulation comprising rpl554
HK40007474A (en) Liquid inhalation formulation comprising rpl554
WO2022007743A1 (zh) 粘膜给药剂型和其应用
HK1233919A1 (en) Liquid inhalation formulation comprising rpl554
HK1233919B (en) Liquid inhalation formulation comprising rpl554
BR112017005050B1 (pt) Composições farmacêuticas líquidas, nebulizador e usos da composição farmacêutica líquida

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200728

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240730

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240730

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240730

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250729

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250729

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20260610

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20260610

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260610

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260611

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260611

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260723

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260723